Om du vill rapportera en biverkning gällande en av Lillys produkter, kontakta oss via e-post på DK_PHv@lilly.com eller på telefon +45 4526 6040. Har du ytterligare medicinska frågor gällande en av Lillys produkter, kontakta oss via länken ovan.
Denna information är endast avsedd för sjukvårdspersonal verksam i Sverige och som svar på din fråga. Informationen nedan är på engelska
In a phase 2, multicenter, randomized, double-blind, placebo-controlled study that evaluated once-weekly dulaglutide in 755 patients with T2DM with or without hypertension, treatment with dulaglutide 1.5 mg, dulaglutide 0.75 mg, or placebo did not demonstrate significant changes within or between groups for
plasma renin activity
levels of serum aldosterone
plasma metanephrines and normetanephrines, or
N-terminal probrain natriuretic peptide.1
At 16 weeks, no correlation was found between these biomarkers and changes in 24-hour SBP.1
A significantly greater reduction from baseline in high-sensitivity C-reactive protein levels was observed in patients who received once-weekly dulaglutide 1.5 mg than in those who received placebo (-0.98 mg/L vs 0.62 mg/L; p<.001).1
1. Ferdinand KC, White WB, Calhoun DA, et al. Effects of the once-weekly glucagon-like peptide-1 receptor agonist dulaglutide on ambulatory blood pressure and heart rate in patients with type 2 diabetes mellitus. Hypertension. 2014;64(4):731-737. http://dx.doi.org/10.1161/HYPERTENSIONAHA.114.03062
Glossary
SBP = systolic blood pressure
T2DM = type 2 diabetes mellitus
Datum fӧr senaste ӧversyn 2020 M01 08